231 related articles for article (PubMed ID: 36849745)
1. T cell egress via lymphatic vessels is tuned by antigen encounter and limits tumor control.
Steele MM; Jaiswal A; Delclaux I; Dryg ID; Murugan D; Femel J; Son S; du Bois H; Hill C; Leachman SA; Chang YH; Coussens LM; Anandasabapathy N; Lund AW
Nat Immunol; 2023 Apr; 24(4):664-675. PubMed ID: 36849745
[TBL] [Abstract][Full Text] [Related]
2. CXCR4 is dispensable for T cell egress from chronically inflamed skin via the afferent lymph.
Geherin SA; Wilson RP; Jennrich S; Debes GF
PLoS One; 2014; 9(4):e95626. PubMed ID: 24752354
[TBL] [Abstract][Full Text] [Related]
3. Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control.
Vianello F; Papeta N; Chen T; Kraft P; White N; Hart WK; Kircher MF; Swart E; Rhee S; Palù G; Irimia D; Toner M; Weissleder R; Poznansky MC
J Immunol; 2006 Mar; 176(5):2902-14. PubMed ID: 16493048
[TBL] [Abstract][Full Text] [Related]
4. CXCR4/ACKR3/CXCL12 axis in the lymphatic metastasis of vulvar squamous cell carcinoma.
Rusetska N; Kowalski K; Zalewski K; Zięba S; Bidziński M; Goryca K; Kotowicz B; Fuksiewicz M; Kopczynski J; Bakuła-Zalewska E; Kowalik A; Kowalewska M
J Clin Pathol; 2022 May; 75(5):324-332. PubMed ID: 33692092
[TBL] [Abstract][Full Text] [Related]
5. IFNγ-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin.
Lane RS; Femel J; Breazeale AP; Loo CP; Thibault G; Kaempf A; Mori M; Tsujikawa T; Chang YH; Lund AW
J Exp Med; 2018 Dec; 215(12):3057-3074. PubMed ID: 30381467
[TBL] [Abstract][Full Text] [Related]
6. CD4+CXCR4highCD69+ T cells accumulate in lung adenocarcinoma.
Wald O; Izhar U; Amir G; Avniel S; Bar-Shavit Y; Wald H; Weiss ID; Galun E; Peled A
J Immunol; 2006 Nov; 177(10):6983-90. PubMed ID: 17082613
[TBL] [Abstract][Full Text] [Related]
7. CXCL12 promotes CCR7 ligand-mediated breast cancer cell invasion and migration toward lymphatic vessels.
Hayasaka H; Yoshida J; Kuroda Y; Nishiguchi A; Matsusaki M; Kishimoto K; Nishimura H; Okada M; Shimomura Y; Kobayashi D; Shimazu Y; Taya Y; Akashi M; Miyasaka M
Cancer Sci; 2022 Apr; 113(4):1338-1351. PubMed ID: 35133060
[TBL] [Abstract][Full Text] [Related]
8. The CXCL12-CXCR4 chemokine pathway: a novel axis regulates lymphangiogenesis.
Zhuo W; Jia L; Song N; Lu XA; Ding Y; Wang X; Song X; Fu Y; Luo Y
Clin Cancer Res; 2012 Oct; 18(19):5387-98. PubMed ID: 22932666
[TBL] [Abstract][Full Text] [Related]
9. Rheumatoid fibroblast-like synoviocytes overexpress the chemokine stromal cell-derived factor 1 (CXCL12), which supports distinct patterns and rates of CD4+ and CD8+ T cell migration within synovial tissue.
Bradfield PF; Amft N; Vernon-Wilson E; Exley AE; Parsonage G; Rainger GE; Nash GB; Thomas AM; Simmons DL; Salmon M; Buckley CD
Arthritis Rheum; 2003 Sep; 48(9):2472-82. PubMed ID: 13130466
[TBL] [Abstract][Full Text] [Related]
10. The CXCL12/CXCR4/ACKR3 Axis in the Tumor Microenvironment: Signaling, Crosstalk, and Therapeutic Targeting.
Smit MJ; Schlecht-Louf G; Neves M; van den Bor J; Penela P; Siderius M; Bachelerie F; Mayor F
Annu Rev Pharmacol Toxicol; 2021 Jan; 61():541-563. PubMed ID: 32956018
[TBL] [Abstract][Full Text] [Related]
11. Regulation of CXCL12 and CXCR4 expression by human brain endothelial cells and their role in CD4+ and CD8+ T cell adhesion and transendothelial migration.
Liu KK; Dorovini-Zis K
J Neuroimmunol; 2009 Oct; 215(1-2):49-64. PubMed ID: 19765831
[TBL] [Abstract][Full Text] [Related]
12. SIRT1 induces the accumulation of TAMs at colorectal cancer tumor sites via the CXCR4/CXCL12 axis.
Fang H; Huang Y; Luo Y; Tang J; Yu M; Zhang Y; Zhong M
Cell Immunol; 2022 Jan; 371():104458. PubMed ID: 34847407
[TBL] [Abstract][Full Text] [Related]
13. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.
Müller N; Michen S; Tietze S; Töpfer K; Schulte A; Lamszus K; Schmitz M; Schackert G; Pastan I; Temme A
J Immunother; 2015 Jun; 38(5):197-210. PubMed ID: 25962108
[TBL] [Abstract][Full Text] [Related]
14. CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche.
Kim M; Koh YJ; Kim KE; Koh BI; Nam DH; Alitalo K; Kim I; Koh GY
Cancer Res; 2010 Dec; 70(24):10411-21. PubMed ID: 21056990
[TBL] [Abstract][Full Text] [Related]
15. Differential regulation of CXCR4-mediated T-cell chemotaxis and mitogen-activated protein kinase activation by the membrane tyrosine phosphatase, CD45.
Fernandis AZ; Cherla RP; Ganju RK
J Biol Chem; 2003 Mar; 278(11):9536-43. PubMed ID: 12519755
[TBL] [Abstract][Full Text] [Related]
16. Enhanced CXCR4 Expression of Human CD8
Burkard T; Dreis C; Herrero San Juan M; Huhn M; Weigert A; Pfeilschifter JM; Radeke HH
Front Immunol; 2021; 12():668884. PubMed ID: 34504486
[TBL] [Abstract][Full Text] [Related]
17. gammadelta T lymphocytes count is normal and expandable in peripheral blood of patients with follicular lymphoma, whereas it is decreased in tumor lymph nodes compared with inflammatory lymph nodes.
Braza MS; Caraux A; Rousset T; Lafaye de Micheaux S; Sicard H; Squiban P; Costes V; Klein B; Rossi JF
J Immunol; 2010 Jan; 184(1):134-40. PubMed ID: 19949101
[TBL] [Abstract][Full Text] [Related]
18. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
[TBL] [Abstract][Full Text] [Related]
19. Breast Cancer: An Examination of the Potential of ACKR3 to Modify the Response of CXCR4 to CXCL12.
Del Molino Del Barrio I; Wilkins GC; Meeson A; Ali S; Kirby JA
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30441765
[TBL] [Abstract][Full Text] [Related]
20. CXCR4, but not CXCR3, drives CD8
Goedhart M; Gessel S; van der Voort R; Slot E; Lucas B; Gielen E; Hoogenboezem M; Rademakers T; Geerman S; van Buul JD; Huveneers S; Dolstra H; Anderson G; Voermans C; Nolte MA
Eur J Immunol; 2019 Apr; 49(4):576-589. PubMed ID: 30707456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
